



## Introduction

Checkpoint inhibitor treatment has become a common therapy of various cancer types. Still, there is a need for well-characterized preclinical mouse models, as clinical data indicates that patients only partially respond to immune-modulatory regiments.

When compared to the classic subcutaneous or subQperior<sup>TM</sup> (implantation into the mammary fat pad) syngeneic mouse models, orthotopic models are considered more predictive since the implantation of tumor cells into the organ of origin allows organotypic interaction between tumor cells and the surrounding stroma, including immune cells.

## Orthotopic HEPA1-6 liver tumor growth can be initiated by different routes of tumor cell implantation:

- Direct injection into the liver lobe in Matrigel
- Via the portal vein
- Via the spleen with subsequent removal of the spleen

The growth of the luciferase-transduced Hepa1-6 cells can be monitored in vivo by bioluminescence imaging.







## COMPARISON AND CONSEQUENCES OF DIFFERENT IMPLANTATION TECHNIQUES ON THE ORTHOTOPIC GROWTH OF SYNGENEIC HEPA1-6 LIVER CANCER CELLS

Cynthia Obodozie, Sandra Moor, Gojko Bijelic, Muriel Malaisé, Philipp Metzger, and Holger Weber

Reaction Biology Europe GmbH, Engesserstr. 4, 79108 Freiburg, Germany

